CL2020003323A1 - Regímenes de dosis para la inhibición dirigida a tgf-b para ser usada en el tratamiento de cáncer del tracto biliar - Google Patents

Regímenes de dosis para la inhibición dirigida a tgf-b para ser usada en el tratamiento de cáncer del tracto biliar

Info

Publication number
CL2020003323A1
CL2020003323A1 CL2020003323A CL2020003323A CL2020003323A1 CL 2020003323 A1 CL2020003323 A1 CL 2020003323A1 CL 2020003323 A CL2020003323 A CL 2020003323A CL 2020003323 A CL2020003323 A CL 2020003323A CL 2020003323 A1 CL2020003323 A1 CL 2020003323A1
Authority
CL
Chile
Prior art keywords
biliary tract
tgf
cancer
dose regimens
treatment
Prior art date
Application number
CL2020003323A
Other languages
English (en)
Spanish (es)
Inventor
Bawab Samer El
Yulia Vugmeyster
Akash Khandelwal
Olaf Christensen
Motonobu Osada
Meng Li
Isabelle Dussault
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of CL2020003323A1 publication Critical patent/CL2020003323A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/844—Liver
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Inorganic Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
CL2020003323A 2018-06-22 2020-12-21 Regímenes de dosis para la inhibición dirigida a tgf-b para ser usada en el tratamiento de cáncer del tracto biliar CL2020003323A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862688476P 2018-06-22 2018-06-22
US201962855205P 2019-05-31 2019-05-31

Publications (1)

Publication Number Publication Date
CL2020003323A1 true CL2020003323A1 (es) 2021-07-23

Family

ID=68982740

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2020003323A CL2020003323A1 (es) 2018-06-22 2020-12-21 Regímenes de dosis para la inhibición dirigida a tgf-b para ser usada en el tratamiento de cáncer del tracto biliar

Country Status (14)

Country Link
US (1) US20210214446A1 (https=)
EP (1) EP3810654A4 (https=)
JP (1) JP2021528399A (https=)
KR (1) KR20210022680A (https=)
CN (1) CN112673020A (https=)
AU (1) AU2019288765A1 (https=)
BR (1) BR112020026159A2 (https=)
CA (1) CA3103908A1 (https=)
CL (1) CL2020003323A1 (https=)
IL (1) IL279647A (https=)
MX (1) MX2020014166A (https=)
SG (1) SG11202012688UA (https=)
TW (1) TW202019959A (https=)
WO (1) WO2019246595A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202304979A (zh) * 2021-04-07 2023-02-01 瑞士商諾華公司 抗ＴＧＦβ抗體及其他治療劑用於治療增殖性疾病之用途
WO2023045141A1 (zh) * 2021-09-26 2023-03-30 上海迈泰君奥生物技术有限公司 一种双功能融合蛋白

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112016014952A2 (pt) * 2014-02-10 2017-09-19 Merck Patent Gmbh Inibição direcionada de tgfbeta
GB201505305D0 (en) * 2015-03-27 2015-05-13 Immatics Biotechnologies Gmbh Novel Peptides and combination of peptides for use in immunotherapy against various tumors
BR112019005964A2 (pt) * 2016-09-27 2019-06-18 Epicentrx, Inc. proteínas de fusão imunomoduladoras
WO2018129331A1 (en) * 2017-01-07 2018-07-12 Merck Patent Gmbh Dosing regimens and dosage forms for targeted tgf-b inhibition

Also Published As

Publication number Publication date
TW202019959A (zh) 2020-06-01
BR112020026159A2 (pt) 2021-04-06
IL279647A (en) 2021-03-01
JP2021528399A (ja) 2021-10-21
WO2019246595A1 (en) 2019-12-26
US20210214446A1 (en) 2021-07-15
SG11202012688UA (en) 2021-01-28
EP3810654A1 (en) 2021-04-28
MX2020014166A (es) 2021-03-09
KR20210022680A (ko) 2021-03-03
CA3103908A1 (en) 2019-12-26
EP3810654A4 (en) 2022-04-20
AU2019288765A1 (en) 2021-01-07
CN112673020A (zh) 2021-04-16

Similar Documents

Publication Publication Date Title
CY1123258T1 (el) Μεθοδος θεραπειας για τον καρκινο
CY1124298T1 (el) Φενφλουραμινη για χρηση στην θεραπευτικη αντιμετωπιση του συνδρομου dravet
MX2024013526A (es) Metodos para tratar canceres y potenciar la eficacia de agentes terapeuticos para el redireccionamiento de celulas t
MX2023007193A (es) Inhibidores de enpp1 y su uso para el tratamiento del cancer.
MX2019013279A (es) Metodos de tratamiento del sindrome de doose utilizando fenfluramina.
MX2020008906A (es) Compuestos con actividad inductora de ferroptosis y métodos de uso de estos.
CL2021002669A1 (es) (divisional de solicitud 3443-2018) tratamientos de cancer.
BR112018008179A2 (pt) peptídeos e peptidomiméticos em combinação com agentes de ativos de células t e/ou agentes de inibição de ponto de verificação para tratamento de câncer
MX2020008680A (es) Terapia de combinacion con apilimod y agentes glutamatergicos.
MX2019009227A (es) Métodos para tratar cáncer con inhibidores de hsp90.
MX389927B (es) Metodos de tratamiento del sindrome de lennox-gastaut con fenfluramina.
BR112018068412A2 (pt) composto, composição farmacêutica, método de tratamento de síndrome mielodisplásica e método para matar uma célula tumoral
CY1123501T1 (el) Χρηση ρεσλιζουμαμπης για τη θεραπευτικη αντιμετωπιση μετριου εως σοβαρου ηωσινοφιλικου ασθματος
MX2018010223A (es) Terapia combinada para tratamiento de cancer de ovario.
CL2020003323A1 (es) Regímenes de dosis para la inhibición dirigida a tgf-b para ser usada en el tratamiento de cáncer del tracto biliar
EA202191165A1 (ru) Элацестрант в комбинации с абемациклибом у женщин с раком молочной железы
MY203645A (en) Ret inhibitor for use in treating cancer having a ret alteration
MX2020001727A (es) Terapia de combinacion.
MX2021004351A (es) Metodo para el tratamiento de miastenia grave.
MX2020004960A (es) Asociacion de activos para tratar el cancer de prostata.
BR112021006318A2 (pt) terapia de combinação para o tratamento de câncer
MX2020008881A (es) Métodos de tratamiento contra el cáncer que comprenden inhibidores de chk1.
MX2021014524A (es) Metodos para tratar canceres del sistema urinario.
CL2019000846A1 (es) Proteína terapéutica.
MX2021000935A (es) Composiciones y metodos terapeuticos para el tratamiento de cancer pancreatico con acido 6,8-bis(bencilsulfanil)octanoico.